Cooperative Agreement U01DK143386
Award Date 9/10/25
Completion Date 8/31/28
Dollars Obligated $195K
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
- This federal Cooperative Agreement award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to evaluate the use of continuous ketone monitors to enable safe use of SGLT inhibitor medications in patients with type 1 diabetes. The $2,257,919 award to the University of California, San Diego (UC San Diego) will support a two-arm, cross-over clinical trial...
- This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to develop and test a risk mitigation strategy using continuous ketone monitoring (CKM) to enable safer use of SGLT2 inhibitors in patients with Type 1 Diabetes (T1D). The $2,477,577 award to Adventist Health System/Sunbelt Inc. (doing business as AdventHealth Orlando) will fund a...
- This Cooperative Agreement award of $2,367,892 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will fund research to develop and evaluate a novel approach to mitigate the risk of diabetic ketoacidosis (DKA) in people with type 1 diabetes (T1D) and chronic kidney disease (CKD) who are taking sodium-glucose cotransporter (SGLT) inhibitor medications. The project aims...
- This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will provide $987,196 to the University of Melbourne in Australia to conduct a randomized-controlled study on the use of continuous glucose and ketone monitoring to minimize diabetic ketoacidosis in individuals with type 1 diabetes treated with the SGLT inhibitor sotagliflozin. The study...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $762,556 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Aurora Health Care, Inc. The award supports the development of a novel, semi-automated self-monitoring feedback system for health promotion in community settings. The project aims to optimize the efficacy of feedback messages related to dietary intake, physical activity, and weight...
- This $166,953 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant was awarded to the Regents of the University of Minnesota, Office of Sponsored Projects Administration, to conduct a pilot, pragmatic, cluster-randomized clinical trial to evaluate the feasibility of an intervention to increase the use of SGLT2 inhibitor medications after...
- The federal Project Grant award, "GLUCOSE PATTERNS AND CLINICAL OUTCOMES IN THE DALLAS HEART STUDY: A PATHWAY TO PRECISION DIABETES - CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS", is provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $819,091 award to The Johns Hopkins University will fund research to use CGM and machine learning methods to identify...
- This $192,215 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) will support a research project titled "Assessing Patient-Centric Factors and Enhancing Risk Communication to Improve Treatment Persistence in Kidney and Cardiovascular Care" at the University of California, San Francisco (UCSF). The project aims to develop an effective risk communication aid to...
- This federal Project Grant award of $1,499,132 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will support a study to examine the impact of the Inflation Reduction Act's insulin affordability provisions on Medicare beneficiaries. The study will leverage data from the OptumLabs Data Warehouse and Medicare claims to assess changes in out-of-pocket insulin costs,...
- This Cooperative Agreement award, in the amount of $816,325.00, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support a collaborative research project to optimize and evaluate novel small molecule "PAIR" inhibitors that target the unfolded protein response (UPR) pathway in pancreatic beta cells, with the goal of preventing and...